MoneyWorks4Me

Medicamen Biotech’s Bhiwadi Formulation facility completes EU GMP Inspection

31 May 2024 Evaluate

The Inspection Department, Division of Production & Distribution Control, National Organisation for Medicines, GREECE, has inspected the General Tablets and Liquid Orals Formulation facility of Medicamen Biotech located at Phase IV, Industrial Area, Bhiwadi from May 28, 2024 and concluded on May 30, 2024.

The inspection closed with some procedural observations which will be well responded within Stipulated time. However, the Final approval (EU GMP Certification) is expected after submission of formal response to Greece Authorities. 

Medicamen Biotech is engaged in manufacturing and marketing of pharmaceutical formulations in overseas and domestic markets.


Medicamen Biotech Share Price

260.35 -3.15 (-1.20%)
03-Sep-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.00
Dr. Reddys Labs. 1155.00
Cipla 1389.00
Lupin 2135.00
Zydus Lifesciences 1135.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: